Zevra Therapeutics develops and sells treatments for rare diseases, including MIPLYFFA for Niemann Pick disease type C. It last closed at $9.40 on Nov 17, up 1.62% on the day. The average 12-month price target from 3 analysts is $19.33 (+105.7% from the last close), with a high of $21.00 and a low of $18.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Each firm's latest rating on ZVRA in the past 90 days
Average 12-month target
$19.33
▲ 105.7% upside
Based on 3 analysts who set a price target on ZVRA in the past 90 days. The average target is $19.33, with a high of $21.00 and a low of $18.00, compared with the last close of $9.40.
Highest target$21.00
Average target$19.33
Lowest target$18.00
Latest rating changes
GuggenheimTarget lowered
Nov 16Buy$23 → $18
BTIGTarget lowered
Nov 13Buy$24 → $21
Cantor FitzgeraldTarget lowered
Nov 13Buy$34 → $19
GuggenheimTarget lowered
Aug 7Buy$24 → $23
CitizensMaintained
Aug 6Buy$28
Date
Firm
Action
Rating
Price target
Nov 16
Guggenheim
Target lowered
Buy
$23 → $18
Nov 13
BTIG
Target lowered
Buy
$24 → $21
Nov 13
Cantor Fitzgerald
Target lowered
Buy
$34 → $19
Aug 7
Guggenheim
Target lowered
Buy
$24 → $23
Aug 6
Citizens
Maintained
Buy
$28
Loading…
Technical Analysis
ZVRA · as of the Nov 17 close · updated after every close
Downtrend
The stock is 11% below its 20 day and 16% below its 50 day average. It is 15% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 40). The nearest support is the swing low (Jul 31) at $9.34, and the nearest resistance the Pivot R1 at $9.52.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 7.0%/day
Key levels
$15.0452 week high+60.0%
$11.44100 day average+21.7%
$10.8650 day average+15.5%
$10.85200 day average+15.4%
$10.55Swing high (Oct 29)+12.2%
$10.4720 day average+11.4%
$9.52Pivot R1+1.3%
$9.40Last close
$9.34Swing low (Jul 31)−0.6%
$9.29Pivot−1.2%
$9.16Pivot S1−2.6%
$8.0152 week low−14.8%
Indicators
RSI (14)
39.85
Weak, oversold below 30
Neutral
MACD
-0.18
Below its signal line
Bearish
Stochastic
9.0
Near the bottom of its range
Oversold
ADX (14)
21.3
Weak trend
Williams %R
-85.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-121.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−8.4%
Change over 10 sessions
Bearish
ATR (14)
$0.66
Typical daily range, 7.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNormal
VolatilityNormal, 15.0%/day
Key levels
$15.0452 week high+60.0%
$11.44100 day average+21.7%
$10.8650 day average+15.5%
$10.85200 day average+15.4%
$10.55Swing high (Oct 29)+12.2%
$10.4720 day average+11.4%
$9.52Pivot R1+1.3%
$9.40Last close
$9.34Swing low (Jul 31)−0.6%
$9.29Pivot−1.2%
$9.16Pivot S1−2.6%
$8.0152 week low−14.8%
Indicators
RSI (14)
44.16
Middle of its range
Neutral
MACD
-0.26
Below its signal line
Bearish
Stochastic
25.3
Middle of its range
Neutral
ADX (14)
18.1
No clear trend
Williams %R
-87.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-135.0
Oversold below −100, overbought above 100
Oversold
Rate of change
−21.7%
Change over 10 sessions
Bearish
ATR (14)
$1.41
Typical daily range, 15.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for ZVRA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ZVRA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow ZVRA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ZVRA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZVRA is in one of them and how their past ZVRA trades turned out.
Zevra Therapeutics develops and sells medicines for rare diseases. Its main approved products are MIPLYFFA, an oral treatment for Niemann Pick disease type C, and OLPRUVA, used to help manage urea cycle disorders in adults and children. The company also has candidates in clinical development, including celiprolol for vascular Ehlers Danlos syndrome. Its products are sold mainly to patients and providers in the United States, and MIPLYFFA is also made available to patients in parts of Europe through an access program. The company is based in Boston, Massachusetts.